argenx SE (A1RG34)
Sao Paulo Exchange · Brazil · prices in BRL · close of 16 Oct 2026
Key indicators
| Last close | BRL 162.13 |
|---|---|
| 52-week range | 143.22 – 213.15 |
| Return, 1 month / 3 months | −21.1% / −8.4% |
| Return, 1 year / 3 years | −7.7% / +61.3% |
| Trend | Below its 200-day average |
| RSI (14) | 19 |
| Volatility (1 year) | 39.7% |
| Worst drawdown (1 year) | -28.5% |
| Average daily value traded | 0.01M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
argenx SE is a biopharmaceutical company that develops antibody-based medicines for people with severe autoimmune diseases. Its main product is an antibody fragment designed to reduce disease-causing antibodies, and it is used to treat generalised myasthenia gravis and other immune-mediated conditions. The company carries out research and clinical development and works with partners to make its medicines available in markets around the world. It is based in the Netherlands, with additional operations in the United States and Europe.
argenx SE is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A1RG34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
argenx SE (A1RG34) trades on the Sao Paulo Exchange in Brazil. It last closed at BRL 162.13 on 16 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 903 of 1,454 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.7% and over the last three months it fell 8.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Sao Paulo Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -7.8% | ||
| From 52-week high | -23.9% | ||
| Momentum | 44 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.4% | ||
| 6-month return | -4.4% | ||
| 12-month return, skipping the last month | 17.0% | ||
| Stability (higher is calmer) | 54 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.5% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M BRL | ||
| Zero-volume days | 56.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −2.0% |
|---|---|
| 1 month | −21.1% |
| 3 months | −8.4% |
| 6 months | −4.4% |
| 1 year | −7.7% |
| 3 years | +61.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 196.84 / 175.75 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.97 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Sao Paulo Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.